Treatment of xerostomia and hyposalivation in the elderly: A systematic review

J-A Gil-Montoya, F-J Silvestre, R Barrios, J Silvestre-Rangil, J-A Gil-Montoya, F-J Silvestre, R Barrios, J Silvestre-Rangil

Abstract

Background: Therapeutic strategies for xerostomia, regardless of etiology, have so far not had definitive or clearly effective results.

Objectives: To systematically revise the latest scientific evidence available regarding the treatment of dry mouth, regardless of the cause of the problem.

Material and methods: The literature search was conducted in March 2015, using the Medline and Embase databases. The "Clinical Trial", from 2006 to March 2015, was carried out in English and only on human cases. The draft of the systematic review and assessment of the methodological quality of the trials was carried out following the criteria of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and the "Oxford Quality Scale".

Results: Finally, a total of 26 trials were identified that met the previously defined selection and quality criteria; 14 related to drug treatments for dry mouth, 10 with non-pharmacological treatment and 2 with alternative treatments.

Conclusions: Pilocarpine continues to be the best performing sialogogue drug for subjects with xerostomia due to radiation on head and neck cancer or diseases such as Sjogren's Syndrome. For patients with dry mouth caused solely by medication, there are some positive indications from the use of malic acid, along with other elements that counteract the harmful effect on dental enamel. In general, lubrication of oral mucous membrane reduces the symptoms, although the effects are short-lived.

Conflict of interest statement

Conflict of interest statement: The authors have declared that no conflict of interest exist.

Figures

Figure 1
Figure 1
Signs and symptoms of hyposalivation in the oral cavity.
Figure 2
Figure 2
PRISMA flow chart to demonstrate the methodology applied to selected articles.

References

    1. Cassolato SF, Turnbull RS. Xerostomia: clinical aspects and treatment. Gerodontology. 2003;20:64–77.
    1. Villa A, Abati S. Risk factors and symptoms associated with xerostomia: a cross-sectional study. Aust Dent J. 2011;56:290–5.
    1. Field EA, Longman LP, Bucknall R, Kaye SB, Higham SM, Edgar WM. The establishment of a xerostomia clinic: a prospective study. Br J Oral Maxillofac Surg. 1997;35:96–103.
    1. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 2003;9:165–76.
    1. Khosravani N, Birkhed D, Ekström J. The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized study. Eur J Oral Sci. 2009;117:209–17.
    1. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev. 2011;12:CD008934.
    1. Furness S, Bryan G, McMillan R, Birchenough S, Worthington HV. Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev. 2013;9:CD009603.
    1. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
    1. O'Connor D, Green S, Higgins JPT. Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S eds. Cochrane Handbook for Systematic Reviews of Intervention. Chicester: Wiley-Blackwell; 2008. pp. 83–94.
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
    1. Kim JH, Ahn HJ, Choi JH, Jung DW, Kwon JS. Effect of 0.1% pilocarpine mouthwash on xerostomia: double-blind, randomised controlled trial. J Oral Rehabil. 2014;41:226–35.
    1. Jha N, Seikaly H, Harris J, Williams D, Sultanem K, Hier M. Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. Head Neck. 2009;31:234–43.
    1. Taweechaisupapong S, Pesee M, Aromdee C, Laopaiboon M, Khunkitti W. Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. Aust Dent J. 2006;51:333–7.
    1. Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial. J Formos Med Assoc. 2006;105:796–803.
    1. Burlage FR, Roesink JM, Kampinga HH, Coppes RP, Terhaard C, Langendijk JA. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys. 2008;70:14–22.
    1. Leung KC, McMillan AS, Wong MC, Leung WK, Mok MY, Lau CS. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol. 2008;27:429–36.
    1. Chambers MS, Posner M, Jones CU, Biel MA, Hodge KM, Vitti R. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68:1102–9.
    1. Jham BC, Teixeira IV, Aboud CG, Carvalho AL, Coelho MM, Freire AR. A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer. Oral Oncol. 2007;43:137–42.
    1. Gómez-Moreno G, Aguilar-Salvatierra A, Guardia J, Uribe-Marioni A, Cabrera-Ayala M, Delgado-Ruiz RA. The efficacy of a topical sialogogue spray containing 1% malic acid in patients with antidepressant-induced dry mouth: a double-blind, randomized clinical trial. Depress Anxiety. 2013;30:137–42.
    1. Gómez-Moreno G, Guardia J, Aguilar-Salvatierra A, Cabrera-Ayala M, Maté-Sánchez de-Val JE, Calvo-Guirado JL. Effectiveness of malic acid 1% in patients with xerostomia induced by antihypertensive drugs. Med Oral Patol Oral Cir Bucal. 2013;18:e49–55.
    1. da Silva Marques DN, da Mata AD, Patto JM, Barcelos FA, de Almeida Rato Amaral JP, de Oliveira MC. Effects of gustatory stimulants of salivary secretion on salivary pH and flow in patients with Sjögren's syndrome: a randomized controlled trial. J Oral Pathol Med. 2011;40:785–92.
    1. Khosravani N, Birkhed D, Ekström J. The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized study. Eur J Oral Sci. 2009;117:209–17.
    1. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20) Arthritis Rheum. 2007;57:310–7.
    1. Sugai S, Takahashi H, Ohta S, Nishinarita M, Takei M, Sawada S. Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial. Mod Rheumatol. 2009;19:114–24.
    1. Gil-Montoya JA, Guardia-López I, González-Moles MA. Evaluation of the clinical efficacy of a mouthwash and oral gel containing the antimicrobial proteins lactoperoxidase, lysozyme and lactoferrin in elderly patients with dry mouth: a pilot study. Gerodontology. 2008;25:3–9.
    1. López-Jornet MP, García-Teresa G, Viñas M, Vinuesa T. Clinical anantimicrobial evaluation of a mouthwash and toothpaste for xerostomia: a randomized, double-blind, crossover study. J Dent. 2011;39:757–63.
    1. McMillan AS, Tsang CS, Wong MC, Kam AY. Efficacy of a novel lubricating system in the management of radiotherapy-related xerostomia. Oral Oncol. 2006;42:842–8.
    1. Kerr AR, Corby PM, Shah SS, Epler M, Fisch GS, Norman RG. Use of a muco-adhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study. J Am Dent Assoc. 2010;141:1250–6.
    1. Frost PM, Shirlaw PJ, Challacombe SJ, Fernandes-Naglik L, Walter JD, Ide M. Impact of wearing an intra-oral lubricating device on oral health in dry mouth patients. Oral Dis. 2006;12:57–62.
    1. Ship JA, McCutcheon JA, Spivakovsky S, Kerr AR. Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J Oral Rehabil. 2007;34:724–32.
    1. Morales-Bozo I, Rojas G, Ortega-Pinto A, Espinoza I, Soto L, Plaza A. Evaluation of the efficacy of two mouthrinses formulated for the relief of xerostomia of diverse origin in adult subjects. Gerodontology. 2012;29:e1103–12.
    1. Femiano F, Rullo R, di Spirito F, Lanza A, Festa VM, Cirillo N. A comparisonof salivary substitutes versus a natural sialogogue (citric acid) in patients complaining of dry mouth as an adverse drug reaction: a clinical, randomized controlled study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;11:e15–20.
    1. Flink H, Tegelberg A, Thörn M, Lagerlöf F. Effect of oral iron supplementation on unstimulated salivary flow rate: a randomized, double-blind, placebo-controlled trial. J Oral Pathol Med. 2006;35:540–7.
    1. Singh M, Stark PC, Palmer CA, Gilbard JP, Papas AS. Effect of omega-3 and vitamin E supplementation on dry mouth in patients with Sjögren's syndrome. Spec Care Dentist. 2010;30:225–9.
    1. Strietzel FP, Lafaurie GI, Mendoza GR, Alajbeg I, Pejda S, Vuletić L. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum. 2011;63:180–90.
    1. Simcock R, Fallowfield L, Monson K, Solis-Trapala I, Parlour L, Langridge C. ARIX: a randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer. Ann Oncol. 2013;24:776–83.
    1. Vivino FB, Al-Hashimi I, Khan Z, Leveque FG, Salisbur PL III, Tran-Johnson TK. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome. Arch Intern Med. 1999;159:174–81.
    1. Sada PR, Isenberg D, Ciurtin C. Biologic treatment in Sjögren's syndrome. Rheumatology (Oxford) 2015;54:219–30.
    1. Robinson PG, Pankhurst CL, Garrett EJ. Randomized-controlled trial: effect of a reservoir biteguard in quality of life of xerostomia. J Oral Pathol Med. 2005;34:193–7.
    1. Saleh J, Figueiredo MA, Cherubini K, Salum FG. Salivary hypofunction: an update on aetiology, diagnosis and therapeutics. Arch Oral Biol. 2015;60:242–55.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren